Ongoing RCC Clinical Trials that may Impact Practice

Author(s):

Pedro Barata, MD, MSc,Martin H. Voss, MD

Pedro Barata, MD, MSc, prompts the panel to share their opinions on which of the discussed clinical trials they find most promising and likely to influence clinical practice in the treatment of renal cell carcinoma.

EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

EP: 5.Exciting Data and Trials in Progress from ASCO 2024

Now Viewing

EP: 6.Ongoing RCC Clinical Trials that may Impact Practice

EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data

EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC

EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

EP: 12.The Role of Chemotherapy in nccRCC Treatment

EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

EP: 14.Final Thoughts/Looking Forward

Please highlight, and ask the panel, which of the discussed studies are most exciting
1. Please mention, and ask the panel, if there are any studies not covered here that are particularly exciting